ATE399542T1 - Alfavbeta3 und alfavbeta6 integrin antagonisten als antifibrotische mittel - Google Patents

Alfavbeta3 und alfavbeta6 integrin antagonisten als antifibrotische mittel

Info

Publication number
ATE399542T1
ATE399542T1 AT04765296T AT04765296T ATE399542T1 AT E399542 T1 ATE399542 T1 AT E399542T1 AT 04765296 T AT04765296 T AT 04765296T AT 04765296 T AT04765296 T AT 04765296T AT E399542 T1 ATE399542 T1 AT E399542T1
Authority
AT
Austria
Prior art keywords
alfavbeta6
alfavbeta3
integrin antagonists
antifibrotic agents
antifibrotic
Prior art date
Application number
AT04765296T
Other languages
English (en)
Inventor
Simon Goodman
Detlef Schuppan
Eleonora Patsenker
Yury Popov
Michael Bauer
Matthias Wiesner
Alfred Jonczyk
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of ATE399542T1 publication Critical patent/ATE399542T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT04765296T 2003-10-01 2004-09-16 Alfavbeta3 und alfavbeta6 integrin antagonisten als antifibrotische mittel ATE399542T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03022048 2003-10-01

Publications (1)

Publication Number Publication Date
ATE399542T1 true ATE399542T1 (de) 2008-07-15

Family

ID=34486055

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04765296T ATE399542T1 (de) 2003-10-01 2004-09-16 Alfavbeta3 und alfavbeta6 integrin antagonisten als antifibrotische mittel

Country Status (18)

Country Link
US (1) US20070117849A1 (de)
EP (1) EP1667668B1 (de)
JP (1) JP4912881B2 (de)
KR (1) KR101191068B1 (de)
CN (1) CN100462068C (de)
AR (1) AR045960A1 (de)
AT (1) ATE399542T1 (de)
AU (1) AU2004283413B2 (de)
BR (1) BRPI0414927A (de)
CA (1) CA2540730C (de)
DE (1) DE602004014795D1 (de)
DK (1) DK1667668T3 (de)
ES (1) ES2308227T3 (de)
MX (1) MXPA06003477A (de)
PL (1) PL1667668T3 (de)
RU (1) RU2388472C2 (de)
WO (1) WO2005039547A1 (de)
ZA (1) ZA200603427B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ535425A (en) 2002-03-13 2008-05-30 Biogen Idec Inc Anti-alphavbeta6 antibodies
GB0722650D0 (en) * 2007-11-19 2007-12-27 Ge Healthcare Ltd Novel imaging method
CN101497656B (zh) * 2009-03-09 2012-08-15 东南大学 与整合素αvβ3具有高结合活性的多肽及其应用
GB0922014D0 (en) 2009-12-17 2010-02-03 Ge Healthcare Ltd Novel integrin binders
HK1208470A1 (en) * 2012-03-29 2016-03-04 Biogen Ma Inc. Biomarkers for use in integrin therapy applications
WO2014015054A1 (en) 2012-07-18 2014-01-23 Saint Louis University Beta amino acid derivatives as integrin antagonists
US8716226B2 (en) 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
PT2953948T (pt) 2013-02-07 2017-12-12 Scifluor Life Sciences Inc Antagonistas de integrina fluorada
WO2014143739A2 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
WO2014144466A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
US9790222B2 (en) 2015-02-19 2017-10-17 Scifluor Life Sciences, Inc. Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
SG11201805387RA (en) 2015-12-30 2018-07-30 Univ Saint Louis Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists
HRP20210228T1 (hr) * 2016-11-08 2021-03-19 Bristol-Myers Squibb Company Amidi pirola kao inhibitori alfa v integrina
BR112019009245A2 (pt) * 2016-11-08 2019-07-16 Bristol-Myers Squibb Company azol amidas e aminas como inibidores de alfav integrina
WO2018106945A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
US20200253506A1 (en) 2016-12-14 2020-08-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
US20230033021A1 (en) 2018-06-20 2023-02-02 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
EP3883635A1 (de) 2018-11-19 2021-09-29 Progenity, Inc. Verfahren und vorrichtungen zur behandlung einer krankheit mit biotherapeutika
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
CN120960406A (zh) * 2024-05-16 2025-11-18 浙江大学 靶向整合素αVβ6的CAR-免疫细胞在预防和/或治疗纤维化疾病中的应用
CN118641765B (zh) * 2024-05-17 2025-06-20 中国医学科学院医药生物技术研究所 Tinagl1在制备抗肝纤维化药物中的应用及化合物的新用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW352384B (en) * 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
PL350057A1 (en) * 1999-02-20 2002-11-04 Merck Patent Gmbh β-ALANINE DERIVATIVES
DE19933173A1 (de) * 1999-07-15 2001-01-18 Merck Patent Gmbh Cyclische Peptidderivate als Inhibitoren des Integrins alpha¶v¶beta¶6¶
DE10006139A1 (de) * 2000-02-11 2001-08-16 Merck Patent Gmbh Indol-3-yl-Derivate
DE10063173A1 (de) * 2000-12-18 2002-06-20 Merck Patent Gmbh Harnstoff- und Urethanderivate
CA2439852A1 (en) * 2001-03-02 2002-09-12 Christine Dingivan Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists
DE10112771A1 (de) * 2001-03-16 2002-09-26 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta¶6¶
AU2002319282B2 (en) * 2001-08-01 2007-06-28 Merck Patent Gmbh Integrin inhibitors for the treatment of eye diseases
US20050085415A1 (en) * 2002-02-14 2005-04-21 Matthias Wiesner Methods and compositions for the treatment of eye diseases

Also Published As

Publication number Publication date
KR20060090818A (ko) 2006-08-16
AU2004283413A1 (en) 2005-05-06
RU2006114395A (ru) 2007-11-27
DK1667668T3 (da) 2008-09-15
KR101191068B1 (ko) 2012-10-15
CA2540730C (en) 2012-08-21
EP1667668A1 (de) 2006-06-14
EP1667668B1 (de) 2008-07-02
PL1667668T3 (pl) 2008-10-31
US20070117849A1 (en) 2007-05-24
WO2005039547A1 (en) 2005-05-06
CN1863520A (zh) 2006-11-15
JP2007507440A (ja) 2007-03-29
AU2004283413B2 (en) 2010-09-02
MXPA06003477A (es) 2006-06-05
BRPI0414927A (pt) 2006-11-07
AR045960A1 (es) 2005-11-16
RU2388472C2 (ru) 2010-05-10
CA2540730A1 (en) 2005-05-06
ES2308227T3 (es) 2008-12-01
ZA200603427B (en) 2007-09-26
DE602004014795D1 (de) 2008-08-14
JP4912881B2 (ja) 2012-04-11
CN100462068C (zh) 2009-02-18

Similar Documents

Publication Publication Date Title
ATE399542T1 (de) Alfavbeta3 und alfavbeta6 integrin antagonisten als antifibrotische mittel
ATE426597T1 (de) Benzamidderivate und deren verwendung als glucokinaseaktivierende mittel
CY2018009I1 (el) Παραλλαγες ανοσοσφαιρινων και χρησεις αυτων
DE60308998D1 (de) N-aryl-2-oxazolidinon-5-carbonsäureamide und deren derivate und deren verwendung als antibakterielle mittel
DE602004012891D1 (de) Pyrido- und pyrimidopyrimidinderivate als anti-proliferative mittel
DE602004021904D1 (de) Gyraseinhibitoren und deren verwendungen
EP1485754A4 (de) Warenanzeigetasche und system
DE602004032276D1 (de) Tetrahydro-Naphthalen und Harnstoffderivate
DE602004020805D1 (de) Weiche und bauschige textilverbundstoffe
ATE543825T1 (de) Spiro-oxindolverbindungen und ihre verwendungen als therapeutische mittel
ATE420084T1 (de) Neue imidazolderivate und deren verwendung als pharmazeutische mittel
DE60214413D1 (de) Thiophen- und thiazolsulfonamide als antineoplastische mittel
EP1832272A4 (de) Modifiziertes pulver und dieses verwendende kosmetische zusammensetzung
ATE486091T1 (de) Vegf-fallen und therapeutische verwendungen dafür
DE60327316D1 (de) Kombination enthaltend valsartan, amlodipin und hydrochlorothiazid
CY2012024I1 (el) Υπο-ακετυλιωμενα και υπερ-ακετυλιωμενα μηνιγγοκοκκικα καψικα σακχαριδια
ATE391531T1 (de) Schweisshemmende mittel
DE60304188D1 (de) Ä1,4ÜDIAZOCINOÄ7,8,1-hiÜINDOLDERIVATE ALS ANTIPSYCHOTISCHE MITTEL UND MITTEL GEGEN OBESITÄT
ATE433448T1 (de) Kondensierte heterocyclen und deren verwendungen
EP1551389A4 (de) Dihydroartemisinin und dihydroartemisiten-dimere als mittel gegen krebs und infektionen
DE60134575D1 (de) Kombination enthaltend einen at1-rezeptor antagonisten und einen insulinsekretion verstärker oder einen insulin sensibilisator
DE60336025D1 (de) Kollimator und bestrahler
DE602005020457D1 (de) Master-slave-flip-flop, trigger-flip-flop und zähler
DE502004006418D1 (de) Heterocyclyl-substituierte dihydrochinazoline und ihre verwendung als antivirale mittel
ATE321761T1 (de) Indolylpiperidinderivate als antihistaminische und antiallergische mittel

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1667668

Country of ref document: EP